Vision RT Voted “Best In Class” For Customer Service And Support By Customers – For The Second Straight Year

News - 15 July 2019

12 July 2019. Independent customer research released today has shown market-leading results for Vision RT, the leading supplier of SGRT, in comparison to other companies in the radiation therapy market.

Vision RT has been named “best in class” for customer service/support by 53% of participants with various other well-known radiation therapy suppliers making up the remainder. This is an improvement on the already-impressive 51% of customers who named Vision RT as best in class, unprompted, in the same research in 2018.

Customers cited product quality, clinical evidence, and quality of service and support as the three main reasons for choosing Vision RT.

The research was performed by ISO27001 accredited agency Savanta (formerly Circle Research), which involved in-depth questioning of 90+ users of SGRT technology across the USA, Europe, and Australia.

Chris Woolcott, Associate Director at Savanta, was “very impressed” by these results. “We perform customer satisfaction research for many companies in the medical field and elsewhere, and Vision RT stand out with the positive feedback they have received from their customers,” he said.

Norman Smith, CEO of Vision RT, commented. “We would like to thank all of our customers for this endorsement of our efforts. We repeated this research to ensure that our customer service continues to improve, and our investments are clearly paying off for customers.  Vision RT continue to be dedicated to achieving customer delight at the highest level, and I am delighted to see that our support teams are delivering this, and improving year on year,” he says.

*Benchmarking data from Savanta (savanta.com).  Includes those outside the medical industry.

Vision RT defines the standard of care in Surface Guided Radiation Therapy. We provide superior solutions for the radiotherapy market, with products installed in many of the leading treatment centers in the world, including around 70% of the 50 US News “Best Hospitals for Cancer”. With 70 granted patents plus 51 pending, we continue to innovate in the radiation oncology space and are committed to making SGRT the standard of care for all patients, worldwide.

Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 18,000 people, with a total revenue of more than $3 billion.